Endothelial cell markers from clinician's perspective
Authorized Users Only
2017
Authors
Rakocević, Jelena
Orlić, Dejan
Mitrović-Ajtić, Olivera

Tomašević, Miloje
Dobrić, Milan
Zlatić, Nataša
Milašinović, Dejan
Stanković, Goran

Ostojić, Miodrag
Labudovic-Borović, Milica
Article (Published version)

Metadata
Show full item recordAbstract
Endothelial cell markers are membrane-bound or cytoplasmic molecules expressed by endothelial cells, which help their easier identification and discrimination from other cell types. During vasculogenesis, endothelial cells differentiate from hemangioblasts to form new blood vessels. With the discovery of endothelial progenitor cells (EPC) and their ability to form new blood vessels, the term vasculogenesis is not only reserved for the embryonic development. Possibility of de novo blood vessel formation from EPC is now widely explored in different ischemic conditions, especially in cardiovascular medicine. Numerous clinical trials have tested enhancing tissue vascularization by delivering hematopoietic cells that expressed endothelial markers. This therapeutic approach proved to be challenging and promising, particularly for patients who have exhausted all conventional therapeutic modalities. Angiogenesis, which refers to the formation of new blood vessels from existing vasculature, is ...indispensable process during tumor progression and metastasis. Blockage of tumor angiogenesis by targeting and inhibiting endothelial cell has emerged as novel safe and efficacious method to control many advanced malignant diseases. Numerous clinical studies are currently testing new antiangiogenic drugs which target and inhibit endothelial cell markers, receptors or molecules which transmit receptor-mediated signals, therefore inhibiting endothelial cell proliferation, migration and vascular tube formation. Many of these drugs are now widely used in clinical settings as first-or second-line chemotherapy in advanced malignant conditions. So far, these therapeutic approaches gave modest, yet encouraging clinical improvements, prolonging survival and improving functional capacity and quality of life for many terminally ill patients. Here we present the most commonly used endothelial cell markers along with their applicability in contemporary clinical practice.
Keywords:
Endothelial cell / Surface marker / CD34 / CD31 / VEGF / VEGFR2Source:
Experimental & Molecular Pathology, 2017, 102, 2, 303-313Publisher:
- Academic Press Inc Elsevier Science, San Diego
DOI: 10.1016/j.yexmp.2017.02.005
ISSN: 0014-4800
PubMed: 28192087
WoS: 000403040200021
Scopus: 2-s2.0-85014539011
Collections
Institution/Community
Institut za medicinska istraživanjaTY - JOUR AU - Rakocević, Jelena AU - Orlić, Dejan AU - Mitrović-Ajtić, Olivera AU - Tomašević, Miloje AU - Dobrić, Milan AU - Zlatić, Nataša AU - Milašinović, Dejan AU - Stanković, Goran AU - Ostojić, Miodrag AU - Labudovic-Borović, Milica PY - 2017 UR - http://rimi.imi.bg.ac.rs/handle/123456789/821 AB - Endothelial cell markers are membrane-bound or cytoplasmic molecules expressed by endothelial cells, which help their easier identification and discrimination from other cell types. During vasculogenesis, endothelial cells differentiate from hemangioblasts to form new blood vessels. With the discovery of endothelial progenitor cells (EPC) and their ability to form new blood vessels, the term vasculogenesis is not only reserved for the embryonic development. Possibility of de novo blood vessel formation from EPC is now widely explored in different ischemic conditions, especially in cardiovascular medicine. Numerous clinical trials have tested enhancing tissue vascularization by delivering hematopoietic cells that expressed endothelial markers. This therapeutic approach proved to be challenging and promising, particularly for patients who have exhausted all conventional therapeutic modalities. Angiogenesis, which refers to the formation of new blood vessels from existing vasculature, is indispensable process during tumor progression and metastasis. Blockage of tumor angiogenesis by targeting and inhibiting endothelial cell has emerged as novel safe and efficacious method to control many advanced malignant diseases. Numerous clinical studies are currently testing new antiangiogenic drugs which target and inhibit endothelial cell markers, receptors or molecules which transmit receptor-mediated signals, therefore inhibiting endothelial cell proliferation, migration and vascular tube formation. Many of these drugs are now widely used in clinical settings as first-or second-line chemotherapy in advanced malignant conditions. So far, these therapeutic approaches gave modest, yet encouraging clinical improvements, prolonging survival and improving functional capacity and quality of life for many terminally ill patients. Here we present the most commonly used endothelial cell markers along with their applicability in contemporary clinical practice. PB - Academic Press Inc Elsevier Science, San Diego T2 - Experimental & Molecular Pathology T1 - Endothelial cell markers from clinician's perspective EP - 313 IS - 2 SP - 303 VL - 102 DO - 10.1016/j.yexmp.2017.02.005 UR - conv_4039 ER -
@article{ author = "Rakocević, Jelena and Orlić, Dejan and Mitrović-Ajtić, Olivera and Tomašević, Miloje and Dobrić, Milan and Zlatić, Nataša and Milašinović, Dejan and Stanković, Goran and Ostojić, Miodrag and Labudovic-Borović, Milica", year = "2017", abstract = "Endothelial cell markers are membrane-bound or cytoplasmic molecules expressed by endothelial cells, which help their easier identification and discrimination from other cell types. During vasculogenesis, endothelial cells differentiate from hemangioblasts to form new blood vessels. With the discovery of endothelial progenitor cells (EPC) and their ability to form new blood vessels, the term vasculogenesis is not only reserved for the embryonic development. Possibility of de novo blood vessel formation from EPC is now widely explored in different ischemic conditions, especially in cardiovascular medicine. Numerous clinical trials have tested enhancing tissue vascularization by delivering hematopoietic cells that expressed endothelial markers. This therapeutic approach proved to be challenging and promising, particularly for patients who have exhausted all conventional therapeutic modalities. Angiogenesis, which refers to the formation of new blood vessels from existing vasculature, is indispensable process during tumor progression and metastasis. Blockage of tumor angiogenesis by targeting and inhibiting endothelial cell has emerged as novel safe and efficacious method to control many advanced malignant diseases. Numerous clinical studies are currently testing new antiangiogenic drugs which target and inhibit endothelial cell markers, receptors or molecules which transmit receptor-mediated signals, therefore inhibiting endothelial cell proliferation, migration and vascular tube formation. Many of these drugs are now widely used in clinical settings as first-or second-line chemotherapy in advanced malignant conditions. So far, these therapeutic approaches gave modest, yet encouraging clinical improvements, prolonging survival and improving functional capacity and quality of life for many terminally ill patients. Here we present the most commonly used endothelial cell markers along with their applicability in contemporary clinical practice.", publisher = "Academic Press Inc Elsevier Science, San Diego", journal = "Experimental & Molecular Pathology", title = "Endothelial cell markers from clinician's perspective", pages = "313-303", number = "2", volume = "102", doi = "10.1016/j.yexmp.2017.02.005", url = "conv_4039" }
Rakocević, J., Orlić, D., Mitrović-Ajtić, O., Tomašević, M., Dobrić, M., Zlatić, N., Milašinović, D., Stanković, G., Ostojić, M.,& Labudovic-Borović, M.. (2017). Endothelial cell markers from clinician's perspective. in Experimental & Molecular Pathology Academic Press Inc Elsevier Science, San Diego., 102(2), 303-313. https://doi.org/10.1016/j.yexmp.2017.02.005 conv_4039
Rakocević J, Orlić D, Mitrović-Ajtić O, Tomašević M, Dobrić M, Zlatić N, Milašinović D, Stanković G, Ostojić M, Labudovic-Borović M. Endothelial cell markers from clinician's perspective. in Experimental & Molecular Pathology. 2017;102(2):303-313. doi:10.1016/j.yexmp.2017.02.005 conv_4039 .
Rakocević, Jelena, Orlić, Dejan, Mitrović-Ajtić, Olivera, Tomašević, Miloje, Dobrić, Milan, Zlatić, Nataša, Milašinović, Dejan, Stanković, Goran, Ostojić, Miodrag, Labudovic-Borović, Milica, "Endothelial cell markers from clinician's perspective" in Experimental & Molecular Pathology, 102, no. 2 (2017):303-313, https://doi.org/10.1016/j.yexmp.2017.02.005 ., conv_4039 .